The price of lorlatinib targeted drug entering into medical insurance

Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that mainly targets ALK (anaplastic lymphoma kinase) and Non-small cell lung cancer (NSCLC) with positive mutations in ROS1(C-rosproto-oncogene1). As a highly selective drug, lorlatinib can effectively inhibit ALK and ROS1 related gene mutations, including resistance mutations generated after first- and second-generation TKI treatment, and significantly extend the patient's progression-free survival (PFS). It is characterized by strong blood-brain barrier penetration and can effectively control brain metastases, making it an important treatment option for advanced patients.

Larlatinib has been launched in China and has been included in the national medical insurance directory. After being included in medical insurance, the price of lorlatinib has been significantly reduced, although the specific reimbursement ratio and payment amount vary depending on regional policies and the patient's personal circumstances. Calculated in terms of medical insurance prices, the average monthly out-of-pocket expenses of patients have dropped significantly from the original high level, and are currently around 10,000 to 20,000 yuan. The specific amount of medical insurance reimbursement depends on local policies and the actual situation of the hospital pharmacy. Patients can consult local medical institutions for more accurate information.

In foreign markets, the price of lorlatinib varies by region. For example, the price of original drugs in Türkiye is relatively affordable, about more than 7,000 yuan per month; while the price of original drugs in Hong Kong, China is relatively expensive, up to 30,000 yuan. In addition, generic drugs produced in Laos and Bangladesh have attracted attention at lower prices, usually ranging from more than one thousand yuan to several thousand yuan. Although the ingredients and efficacy of generic drugs are basically the same as those of original drugs, the production standards and quality management may be slightly different. It is recommended to purchase them through formal channels.

The inclusion of lorlatinib in medical insurance has reduced the financial burden for many patients with ALK or ROS1 positive lung cancer, improved drug accessibility, and provided important support for the treatment of complex conditions such as drug resistance and brain metastasis. However, patients need to strictly follow the doctor's medication instructions and choose a suitable drug source based on their personal financial situation to ensure treatment effectiveness and safety.

xa0

References:

China National Medical Products Administration: https://www.nmpa.gov.cn/